Eli Lilly and Company has presented the new data demonstrating that knowledge of amyloid status as specified by Florbetapir F 18 Injection imaging, altered diagnosis and management in the majority of patients being studied.

The multicentre trial was designed to assess the impact of amyloid positron emission tomography (PET) on patient management and outcomes in a randomised and controlled setting.

Presented along with its subsidiary Avid Radiopharmaceuticals, the results also demonstrated that knowledge of amyloid status as determined by florbetapir imaging changed patient management in the majority of study patients, specifically Alzheimer’s disease medications, in a direction consistent with amyloid status.

Avid Radiopharmaceuticals clinical development vice-president Dr Michael Pontecorvo said: "These study results are the first to suggest in a controlled study that adding florbetapir to the diagnostic evaluation changed actual patient diagnosis and management by physicians who regularly manage this complicated and devastating disease."

"Adding florbetapir to the diagnostic evaluation changed actual patient diagnosis and management by physicians who regularly manage this complicated and devastating disease."

Using the randomised and controlled prospective design, the study observed the impact of amyloid imaging on diagnosis and actual patient management.

Physicians recorded a working diagnosis and management plan, after identifying patients seeking diagnosis for mild impairment or dementia, where Alzheimer’s disease was considered a possible cause.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The patients later completed a florbetapir PET scan and were then randomised to either immediate or delayed (one year) feedback groups regarding amyloid status.

In the study, the firms randomised 618 subjects to the immediate (308) or to the delayed (310) amyloid PET feedback arms, comprising 174 subjects in France, 221 in Italy, and 223 in the US.

The 602 subjects completed the three-month and 560 completed the one-year follow-up visits.